A Long-term Safety Study of a Second Treatment with Darvadstrocel for Treating Complex Perianal Fistulas in Adults with Crohn's Disease

Overview

Sponsor-declared trial summary

Key facts

Sponsor

Takeda Development Center Americas Inc.

Participant type

Patients

Age range

18-64 years, 65+ years

Gender

Male and Female

Therapeutic area

Diseases [C] - Digestive System Diseases [C06]

Trial duration

3 Jun 2020 → 15 Feb 2025

Decision date (initial)

2023-12-18

Transition trial

Yes

Low-intervention

No

Rare-disease indication

Yes

Vulnerable population

Yes

Funding sources

Takeda Development Center Americas Inc.

External identifiers

EU CT number

2022-503014-23-00

EudraCT number

2017-002491-10

WHO UTN

U1111-1237-8388

ClinicalTrials.gov

NCT04118088

Trial design

CTIS Part I — objectives, methods, condition coding

Main objective

Scope: Safety, Efficacy

To evaluate the long-term safety of repeat administration of darvadstrocel in subjects with CD and complex perianal fistula by evaluation of AEs, serious adverse events (SAEs), adverse events of special interest (AESIs), and pregnancy.

Secondary objectives 1

1. To evaluate the long-term efficacy of repeat administration of darvadstrocel in subjects with CD and complex perianal fistula.

Conditions and MedDRA coding

Perianal fistulising Crohn´s disease

Study design 1 period

Regulatory references

Scientific advice from competent authorities

European Medicines Agency

Plan to share IPD

Yes

IPD plan description

Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Eligibility criteria

Principal inclusion / exclusion criteria as submitted by sponsor

Inclusion criteria 8

1. In the opinion of the investigator, the subject is capable of understanding and complying with protocol requirements.
2. The subject signs and dates a written, informed consent form (ICF) and any required privacy authorization before the initiation of any study procedures.
3. The subject is male or female and aged 18 years or older.
4. The subject has complex perianal fistula(s) with a maximum of 2 internal openings and a maximum of 3 external openings based on clinical assessment and a reading of a locally performed contrast enhanced (gadolinium) pelvic MRI. Fistula(s) must have been draining for at least 6 weeks prior to baseline visit. A complex perianal fistula is defined as a fistula that meets 1 or more of the following criteria: a) High inter-sphincteric, high trans-sphincteric, extrasphincteric or suprasphincteric. b) Presence of ≥2 external openings. c) Associated perianal abscess(es). Note: Abscesses that are larger than 2 cm in at least 2 dimensions on MRI must be confirmed to have been drained
5. The subject has already received treatment with darvadstrocel for a complex perianal fistula at least 6 months prior to baseline visit for retreatment, and their physician has planned a repeat treatment administration for the original tract (full remission not obtained or relapse of fistula draining) or for a new complex perianal fistula tract.
6. The subject has controlled or mildly active CD (defined as patient reported outcomes measure derived from Crohn’s Disease Activity Index [CDAI] patient reported outcome score-2 [PRO-2] score <14).
7. A male subject who is nonsterilized and sexually active with a female partner of childbearing potential agrees to use barrier method of contraception (eg, condom with or without spermicide) from signing of informed consent and until 1 year after repeat administration.
8. A female subject of childbearing potential who is sexually active with a nonsterilized male partner agrees to use a highly effective/effective method of contraception from signing of informed consent and until 1 year after repeat administration.

Exclusion criteria 20

1. The subject has lack of clinical response to prior treatment with darvadstrocel, where clinical response is defined as closure of at least 50% of all treated external fistula openings that were draining at baseline despite gentle finger compression or in the case of a unique fistula, a partial closure of the fistula.
2. The subject has a history of hypersensitivity or allergies to darvadstrocel or related compounds.
3. 3. The subject has a history of hypersensitivity or allergies to penicillin or to aminoglycosides; Dulbecco modified eagle medium; bovine serum; local anesthetics or gadolinium.
4. 4. The subject is currently participating in a double-blind clinical study with darvadstrocel. Subjects participating in the ongoing INSPIRE (Alofisel-5003) registry study would need to withdraw from that study in order to enroll in this study.
5. The subject is currently receiving or has received any other IMP within the last 3 months or at least 5 times the respective elimination half-life time, whichever is longer, before signing the ICF.
6. The subject has known or suspected COVID-19 by the investigator within the past 2 months (additional testing may be performed at the discretion of the investigator). Positive antibody testing for COVID without other evidence of current or recent active infection does not exclude participation. Subjects who were in screening at the time that COVID-19– related factors resulted in discontinuation may also be rescreened with approval of the sponsor or designee.
7. The subject has major alterations in any of the following laboratory tests: a) Serum creatinine levels >1.5 times the upper limit of normal (ULN). b) Total bilirubin >1.5 × ULN. c) Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3.0 × ULN. d) Hemoglobin <10.0 g/dL. e) Platelets <75.0 × 109/L. f) Albumin <3.0 g/dL.
8. 8. The subject has an increased risk for a surgical procedure.
9. The subjects has a known chronically active hepatopathy of any origin, including cirrhosis and subjects with persistent positive hepatitis B surface antigen and quantitative hepatitis B virus polymerase chain reaction (PCR) or positive serology for hepatitis C virus (HCV) and quantitative HCV PCR within 6 months before the baseline visit.
10. If female, the subject is pregnant or breastfeeding, or intending to become pregnant before participating in this study, during the study, or intending to donate ova during such time period.
11. If male, the subject intends to donate sperm during this study.
12. The subject has a contraindication to MRI scan (eg, due to the presence of pacemaker, hip replacement, severe claustrophobia, or renal insufficiency as defined by local clinical guidelines).
13. The subject has a contraindication to the anesthetic procedure.
14. The subject has severe rectal and/or anal stenosis that would make it impossible to follow the surgery procedure.
15. The subject has severe proctitis (rectal ulcers >0.5 cm) that would make it impossible to follow the surgery procedure.
16. The subject has any prior invasive malignancy diagnosed within the last 3 years before baseline visit. Subjects with basal cell carcinoma of the skin completely resected outside the perineal region can be included.
17. The subject has a current or recent (within 6 months before the baseline visit) history of severe, progressive, and/or uncontrolled hepatic, hematologic, gastrointestinal (other than CD), renal, endocrine, pulmonary, cardiac, neurologic, or psychiatric disease that may result in subject’s increased risk from study participation and/or lack of compliance with study procedures.
18. The subject has had major surgery of the gastrointestinal tract within 6 months before baseline or any minor surgery of the gastrointestinal tract 3 months before baseline.
19. The subject has had local major perianal surgery and/or treatment with darvadstrocel within 6 months before baseline. The abscess drainage, cleaning surgery, or seton placement are not considered as “local major surgery” in this protocol.
20. The subject does not wish to or cannot comply with study procedures.

Endpoints

Primary and secondary outcome measures (English text)

Primary endpoints 1

1. • Treatment-emergent AEs • Treatment-emergent SAEs • Pregnancy • Specific treatment-emergent AESIs: immunogenicity/alloimmune reactions; hypersensitivity; transmission of infectious agents; tumorgenicity, applying to malignant tumors only; ectopic tissue formation; medication errors (reported to the pharmacovigilance department as special situation reports)

Secondary endpoints 7

1. Proportion of subjects achieving combined remission of perianal fistulas at Weeks 24 and 156 after darvadstrocel repeat administration. Combined remission is defined as: closure of all treated external openings that were draining at baseline, despite gentle finger compression, AND absence of collections >2cm (in at least 2 dimensions) of the treated perianal fistulas confirmed by centrally read MRI.
2. Proportion of subjects who achieve clinical remission at Weeks 6, 24, 52, 104, and 156 after darvadstrocel repeat administration. Clinical remission is defined as closure of all treated external fistula openings that were draining at baseline despite gentle finger compression.
3. Proportion of subjects who achieve clinical response at Weeks 6, 24, 52, 104, and 156 after darvadstrocel repeat administration. Clinical response is defined as closure of at least 50% of all treated external fistula openings that were draining at baseline despite gentle finger compression.
4. Proportion of subjects with relapse from Week 24 combined remission, where relapse is defined as: a) Reopening of any of the treated fistula(s) external openings with active draining as clinically assessed, thatwere in combined remission at Week 24, OR b) The development of a collection >2 cm (in at least 2 dimensions) of the treated perianal fistula(s) confirmed by centrally read MRI assessment.
5. Time to reopening of any of the treated external openings with active drainage as clinically assessed, measured in days relative to Week 24.
6. Proportion of subjects with new perianal abscess in treated fistula.
7. Change from baseline to Weeks 6, 24, 52, 104, and 156 after darvadstrocel repeat administration in scores of discharge and pain items of Perianal Disease Activity Index (PDAI) score.

Investigational products

Investigational medicinal products (IMPs), comparators, placebo, auxiliary

Test 1

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Takeda Development Center Americas Inc.

Sponsor organisation

Takeda Development Center Americas Inc.

Address

95 Hayden Avenue

City

Lexington

Postcode

02421-7942

Country

United States

Scientific contact point

Organisation

Takeda Development Center Americas Inc.

Contact name

Kabir Ahmed

Public contact point

Organisation

Takeda Development Center Americas Inc.

Contact name

Takeda

Third parties 4

Locations

5 EU/EEA countries · 13 investigational sites

By country

Investigational sites

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Results and documents

Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial

Summary of results Art. 37(4) CTR

Layperson summary Annex V

Documents 9 files

Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.

Application history

4 submissions — initial application plus substantial / non-substantial modifications